Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Biological: TroVax® (Immunological Vaccine Therapy)Drug: Interferon-alpha
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT00445523
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 71
- Registration Number
- NCT00445042
- Locations
- 🇺🇸
Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00440973
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
Not Applicable
Withdrawn
- Conditions
- Central Nervous System TumorsLymphoma
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Registration Number
- NCT00109798
© Copyright 2025. All Rights Reserved by MedPath